At a glance
ClinicalIndex Comparison RecordN/ATerminated· 59 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Clinical and Genomic Analysis on Long-term Survivors of EGFR Mutation Positive Advanced Non-small-cell Lung Cancer Patients With Gefitinib Treatment in China
In Brief
An observational study for EGFR Mutation Positive Advanced Non-small-cell Lung Cancer. Terminated early, enrolled 59 participants across 14 sites.
Signals
Trial was terminated early
Detailed Summary
The primary objective is to describe the genomic profile of long-term survivors, especially to find out potential genomic prognosis and/or predictive factors for gefitinib long-term efficacy as compared to rapid PD patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
N/ATerminatedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartOct 2016
Primary CompletionJul 2017
TodayJul 2026
First PostedOct 13, 2016
Enrollment StartOct 31, 2016
Primary CompletionJul 4, 2017
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 9.7 years ago